Replies to post #836 on Galectin Therapeutics Inc. (GALT)

[pugdaddy]

A few folks have opined that the recent value range ($13-$17) had already accounted for - or presumed - the excellent Phase 1 results. And that therefore there's no reason to expect an increase in share price or valuation any time soon.

I'm personally at a loss to understand that line of reasoning. Was "the market" all THAT certain that the first clinical trial results would be this great?
And was the run-up in price, ever since last summer when these trials began, really based on such an ASSUMPTION?

Or am I missing something here? Any thoughts,anyone? Thanks -